TheraSense Continuous Glucose Monitor R&D To Get Boost From IPO
This article was originally published in The Gray Sheet
Ongoing development of TheraSense's continuous glucose monitoring system will be funded in part through a planned initial public offering of up to $115 mil. in common stock.
You may also be interested in...
Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.